Dates not reported
JASON R. MONEY
JASON R. MONEY appears as a registered lobbyist in federal Lobbying Disclosure Act records connected to organizations tracked by Paper Trail.
Source-backed chronology
Career Timeline
Federal LDA filings
Lobbying Activity
Registrant: CENCORA, INC. · Pharmacy
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. H.R. 1934, The Cancer Care Payment Reform Act of 2015. H.R.5122 - To prohibit further action on the proposed Medicare Part B Provider Reimbursement Demonstration Project through CMS/CMMI, Medicare Access and CHIP Reauthorization Act (MACRA) implementation.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
H.R. 471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015. H.R.5951 and S. 3308, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017.
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act. S. 413 and H.R. 1038 Medicare Part D and Pharmacy Reimbursement.
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 1920 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. H.R. 1834 & S. 463, The Cancer Care Payment Reform Act of 2017. CMS, OMB, HHS, White House Domestic Policy Council, Medicare Part B Reimbursement, Medicare Part D Pharmacy Reimbursement.
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management, including S. 776 The Medication Therapy Management Empowerment Act of 2015.
LDA filing ↗Registrant: CENCORA, INC. · Agriculture
Implementation of the Veterinarian Food Directive; Antimicrobial Resistance.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts. CMS Medicare Part B Drug Payment Model. H.R. 1934, The Cancer Care Payment Reform Act of 2015.
LDA filing ↗Registrant: CENCORA, INC. · Medicare/Medicaid
H.R. 696 & S. 506 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). H.R. 1416 legislation to exclude cancer drugs from sequestration cuts.
LDA filing ↗Registrant: CENCORA, INC. · Taxation/Internal Revenue Code
Repeal of LIFO (last in, first out).
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
H.R.471 & S. 483 legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 314, Provide for coverage under Medicare program of pharmicist services
LDA filing ↗Registrant: CENCORA, INC. · Pharmacy
Enactment of S.483 (114th Congress)legislation to prevent and reduce prescription drug abuse. H.R. 592 & S. 109, Provide for coverage under Medicare program of pharmacist services. Medication Therapy Management H.R. 1038 and S. 413, legislation to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of the Drug Quality Security Act Prescription Drug Importation including S.771 & H.R. 1776, the Improving Access to Affordable Prescription Drugs Act and S. 469, the Affordable and Safe Prescription Drug Importation Act.
LDA filing ↗Registrant: CENCORA, INC. · Agriculture
Implementation of the Veterinarian Food Directive; Antimicrobial Resistance.
LDA filing ↗